Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.
Sean P KennedyJeremy Z R HanNeil PortmanMax NobisJordan F HastingsKendelle J MurphySharissa L LathamAntonia L CadellDushan MiladinovicGabriella R MarriottYolande E I O'DonnellRobert F ShearerJames T WilliamsAmaya Garcia MunozThomas R CoxD Neil WatkinsDarren N SaundersPaul TimpsonElgene LimWalter KolchDavid R CroucherPublished in: Breast cancer research : BCR (2019)
The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.